

IMPROVING PATIENT OUTCOMES IN THYROID DISORDERS THROUGH COLLABORATION BETWEEN SURGERY PHYSICIANS, NURSES, PHARMACISTS, AND LABORATORY STAFF

ABDULRAHMAN MOHAMMED ASHEHRI^{1*}, AHMED ABDULRAHMAN ALBALAWI¹, ABDULAZIZ SALEH M ALFURAYH², DUAA SALEH ALMULHIM³, TURKI HASHER ALOTAIBI⁴, ABDULLAH SAEED AHMED ALASHAARABI⁵, SAAD SAGR SAAD ALSHAHRANI⁵, SALEH GHANNAM ALMUTAIRI⁶, NAJLA ADEL AL OTAIBI⁷, BANDAR MOGTHEL ALMOTAIRI⁸, AFNAN AWDAAH ALSHAHRANI⁹, SAAD ABDULLAH S SHAIBAN¹⁰

¹ SENIOR REGISTRAR GENERAL SURGERY, KING SALMAN ARMED FORCED HOSPITAL, TABUK, SAUDI ARABIA.

² GENERAL PRACTITIONER, EMERGENCY DEPARTMENT, RAFHA CENTRAL HOSPITAL, RAFHA, SAUDI ARABIA

³ PHARMACIST, KING FAHAD MILITARY MEDICAL COMPLEX, DHAHRAN, SAUDI ARABIA

⁴ PHARMACY TECHNICIAN, AL KHARJ ARMED FORCES HOSPITAL, ALKHARJ, SAUDI ARABIA

⁵ MEDICAL LABORATORY TECHNICIAN, ASEER ARMED FORCES HOSPITAL SOUTHERN REGION, ASEER, SAUDI ARABIA

⁶ NURSE TECHNICIAN, MEDICAL CENTER AT KING SALMAN AIR BASE, RAIYADH, SAUDI ARABIA

⁷ NURSING TECHNICIAN, PRINCE SULTAN MILITARY MEDICAL CITY, RIYADH, SAUDI ARABIA

⁸ NURSING SPECIALIST, PRINCE SULTAN MILITARY MEDICAL CITY, RIYADH, SAUDI ARABIA

⁹ PHARMACIST, WADI AL DAWASER ARMED FORCES HOSPITAL, WADI AL DAWASER, SAUDI ARABIA

¹⁰ GENERAL PRACTITIONER, PRINCE SULTAN MILITARY MEDICAL HOSPITAL, RIYADH, SAUDI ARABIA

*Email of the corresponding author: Abdulrahman507@hotmail.com

Abstract

This research paper examines the critical role of interprofessional collaboration (IPC) in improving outcomes for patients with thyroid disorders. Given the high prevalence, non-specific symptomatology, and chronic nature of conditions like hypothyroidism and hyperthyroidism, traditional, siloed care models often lead to diagnostic delays, suboptimal treatment, and significant economic burden. This study argues that a synergistic team-based approach, integrating the unique expertise of Surgery physicians, nurses, pharmacists, and laboratory staff, is essential for effective management. The paper deconstructs the specific and complementary roles of each collaborator and explores practical models for implementation, such as shared care protocols, pharmacist-led clinics, and structured interprofessional huddles. It further analyzes the measurable positive impact of collaboration on key outcomes, including biochemical control, patient-reported quality of life, medication safety, and healthcare utilization. While acknowledging significant barriers, such as professional hierarchies, ambiguous scopes of practice, and misaligned payment models—the research concludes with a strategic roadmap for integration. This roadmap emphasizes policy reform, operational redesign, interprofessional education, and targeted future research to translate the collaborative model into a sustainable, patient-centered standard of care, ultimately enhancing clinical, humanistic, and economic results for this large patient population.

Keywords

Thyroid Disorders, Interprofessional Collaboration, Patient Outcomes, Surgery Physician, Nursing Role, Pharmacist Role, Laboratory Staff.

INTRODUCTION

Thyroid disorders, encompassing hypothyroidism, hyperthyroidism, thyroiditis, and thyroid nodules, represent a pervasive and growing global health concern. With an estimated prevalence affecting hundreds of millions

worldwide—and hypothyroidism alone impacting approximately 5% of the global adult population—these conditions present a substantial burden on healthcare systems and individual well-being [1]. The clinical manifestations of thyroid dysfunction are notoriously protean, affecting nearly every organ system. Symptoms can range from the subtle and non-specific, such as fatigue, weight changes, and mild mood disturbances, to the severe and life-threatening, including myxedema coma or thyroid storm. This wide spectrum of presentation creates a significant diagnostic and management challenge, often leading to delays in identification, misdiagnosis, and suboptimal therapeutic outcomes [2].

Traditionally, the management of thyroid disorders has been viewed primarily through a specialist-centric lens, with endocrinologists at the helm of diagnosis and long-term care. While specialist expertise remains invaluable, particularly for complex cases, this model reveals critical limitations in the face of rising disease prevalence and increasing pressures on specialist services. Long waiting times for endocrine consultations, fragmented communication, and the inherent challenge of coordinating chronic care across disparate healthcare touchpoints can result in treatment lapses, poor medication adherence, and ultimately, worse patient outcomes [3]. Furthermore, the majority of patients with thyroid disorders, especially stable hypothyroid patients, spend most of their healthcare journey interacting not with specialists, but with primary and community-based care providers. This reality underscores the urgent need to reimagine the care pathway from a siloed, hierarchical model to an integrated, collaborative one.

The cornerstone of this new paradigm is the recognition that optimal thyroid care is not the sole responsibility of a single discipline but a collective endeavor. It requires the seamless integration of skills, perspectives, and ongoing monitoring efforts of a multidisciplinary team. At the center of this team is the **surgery physician**, who acts as the first point of contact, the longitudinal coordinator of care, and the diagnostician attuned to the subtle, early signs of dysfunction within the context of the patient's full medical and psychosocial history [4]. The **nurse**, particularly those in primary care or specialized roles, provides indispensable continuity. Through patient education, symptom assessment, titration monitoring, and empathetic support, nurses empower patients to engage actively in their own care, address fears and misconceptions, and improve self-management—a critical component in a condition requiring lifelong levothyroxine therapy for many [5].

The **pharmacist** contributes a unique and vital layer of expertise that directly impacts therapeutic efficacy and safety. Beyond dispensing, pharmacists are frontline experts in pharmacotherapy. They ensure the appropriate administration of thyroid medications (e.g., timing relative to food, supplements, and other drugs), identify potential drug-interactions that could alter thyroid hormone absorption or metabolism, and counsel patients on adherence strategies. Their intervention is crucial in preventing therapeutic failures that stem not from the diagnosis itself, but from how the medication is taken [6]. Finally, the **laboratory staff and clinical biochemists** form the foundation of objective data upon which all clinical decisions rest. Their role extends far beyond performing assays; it involves ensuring the precision and accuracy of thyroid function tests (TSH, Free T4, Free T3), understanding factors that can interfere with results (e.g., heterophilic antibodies, biotin supplementation), and providing clear, timely reporting. Effective communication from the laboratory regarding anomalous results or necessary test repetitions can prevent diagnostic errors and guide appropriate clinical action [7].

The theoretical and practical framework supporting such an approach is **interprofessional collaboration (IPC)**. IPC is defined as a process where multiple health and social care professionals from different backgrounds work together with patients, families, and communities to deliver the highest quality of care [8]. In the context of chronic disease management like thyroid disorders, IPC moves beyond mere referral or information sharing to active, team-based planning and shared decision-making. Models of chronic care, such as the Chronic Care Model (CCM) and the concept of the Patient-Centered Medical Home (PCMH), explicitly identify prepared, proactive practice teams and effective clinical information systems as essential elements for improving outcomes [9]. For thyroid care, this translates to structured pathways where each professional's input is systematically valued and integrated: from the nurse-led annual review checklist and the pharmacist's medication therapy management (MTM) session, to the laboratory's flagging of discordant results for the physician's review, all coordinated under the family physician's oversight.

The potential benefits of such collaboration are multifaceted. For the *patient*, it promises more accessible, continuous, and comprehensible care, leading to better symptom control, improved quality of life, and reduced risk of complications [10]. For the *healthcare system*, it can enhance efficiency by reducing unnecessary specialist referrals, minimizing duplicate testing, preventing medication errors, and lowering the long-term costs associated with poorly managed chronic disease [11]. For the *healthcare professionals themselves*, collaborative practice can reduce individual workload burden, enhance professional satisfaction through role clarity and mutual support, and foster a collective learning environment [12].

However, the transition to a truly collaborative model is fraught with barriers. These include entrenched professional hierarchies, lack of time and dedicated resources for team meetings, incompatible electronic health record systems that impede information sharing, and ambiguities around scope of practice and leadership responsibilities [13].

The Clinical and Economic Burden of Thyroid Disorders: Justifying a Team-Based Approach

Thyroid disorders constitute a significant and pervasive global health challenge, extending far beyond a simple endocrine imbalance to impact patients' quality of life, healthcare system resources, and broader economic productivity. The sheer scale of their prevalence provides the first compelling argument for a systematic, team-based model of care. Hypothyroidism alone is estimated to affect between 2% and 5% of the global population, with its incidence rising sharply with age and being notably higher in women [14]. Hyperthyroidism, while less common, still impacts a substantial number of individuals, with Graves' disease being its most frequent cause. Furthermore, the detection of thyroid nodules via palpation and ultrasound is exceedingly common, found in up to 50-60% of the population, creating a massive cohort requiring surveillance and, in some cases, intervention to rule out malignancy [15]. This high prevalence translates into millions of primary care consultations, laboratory tests, and prescriptions annually, placing thyroid disorders among the most frequently managed conditions in general practice. The traditional, often fragmented, model of care—where patients may shuttle between a busy family doctor, a distant endocrinologist, a separate pharmacy, and a disconnected laboratory—is ill-equipped to handle this volume efficiently and effectively, leading to system strain and potential gaps in care.

The clinical burden of these disorders is profoundly magnified by their insidious and nonspecific symptomatology, which creates a complex diagnostic labyrinth. A patient presenting with fatigue, weight gain, brain fog, and mild depression could be suffering from hypothyroidism, but these same symptoms are hallmarks of numerous other conditions, including depression itself, sleep apnea, or chronic fatigue syndrome [16]. Conversely, symptoms of hyperthyroidism—such as anxiety, palpitations, heat intolerance, and weight loss—can easily be misattributed to stress, anxiety disorders, or menopausal changes. This diagnostic ambiguity often leads to significant delays in diagnosis, sometimes lasting years, during which time patients suffer from a diminished quality of life and may undergo unnecessary and costly investigations for other conditions. Even after diagnosis, the clinical journey remains fraught with challenges. Achieving and maintaining euthyroidism (a balanced thyroid state) is a delicate and individualized process. Levothyroxine, one of the most prescribed medications in the world, has a narrow therapeutic index and its absorption can be adversely affected by a host of common factors including food, supplements like calcium and iron, coffee, and other medications [17]. A patient's required dosage can also fluctuate due to age, weight changes, pregnancy, or the development of concurrent illnesses. Without consistent, nuanced monitoring and patient education—tasks too vast for a single practitioner—suboptimal control is common, leaving patients in a state of persistent, low-grade symptoms that they may incorrectly accept as normal.

The economic ramifications of poorly managed thyroid disease are staggering, encompassing both direct medical costs and indirect costs related to lost productivity. Direct costs include repeated physician visits, frequent laboratory testing (TSH, Free T4, thyroid antibodies), imaging studies for nodule surveillance, specialist referrals, medication costs, and the management of complications arising from untreated or poorly controlled disease. For instance, untreated hypothyroidism can exacerbate cardiovascular risk factors like hyperlipidemia and hypertension, leading to more expensive cardiac care down the line [18]. Uncontrolled hyperthyroidism poses a risk for atrial fibrillation, osteoporosis, and thyroid storm—a medical emergency requiring intensive care. The indirect economic burden is perhaps even more consequential on a societal level. The chronic fatigue, cognitive impairment ("brain fog"), and mood disturbances associated with thyroid dysfunction directly impair work performance, increase absenteeism (sick leave), and reduce presenteeism (working while unwell and thus being less productive) [19]. Studies have shown that workers with untreated or poorly managed hypothyroidism report significantly higher rates of work disability and productivity loss compared to their healthy counterparts. When multiplied across the vast prevalence of the disease, the aggregate loss in national productivity becomes a serious economic concern.

This combination of high prevalence, diagnostic complexity, and substantial clinical and economic burden exposes the critical vulnerabilities of a siloed care model. The family physician, operating alone, may lack the time for the in-depth education required for proper levothyroxine administration. The pharmacist, unaware of the latest TSH results, may dispense the medication without crucial counseling on timing. The laboratory, reporting an abnormal value, may send it into a void without a system to ensure it is seen and acted upon promptly. The nurse, who might be the professional most likely to receive a patient's call about ongoing symptoms, may not have a protocol to adjust a dose or order a follow-up test. This fragmentation leads to redundant tests, medication errors, delayed treatment adjustments, patient frustration, and ultimately, higher costs for inferior outcomes. It is a system that is both inefficient and ineffective.

Therefore, the profound and multifaceted burden of thyroid disorders does not merely *allow* for a team-based approach; it *demand*s it. The clinical complexity requires the combined surveillance of the physician and nurse; the pharmacological precision necessitates the expertise of the pharmacist; the diagnostic accuracy relies on the vigilance of the laboratory professional. An integrated, collaborative model is not a luxury but a necessary response to a public health challenge of this scale. By leveraging the distinct skills of each profession in a coordinated system, care becomes more proactive, preventive, and patient-centered. This synergy has the potential to streamline the diagnostic pathway, optimize medication management to achieve faster and more stable euthyroidism, prevent costly complications, empower patients through consistent education, and reduce the overall economic drag of the disease. In essence, addressing the heavy burden of thyroid disorders requires distributing its weight across the strong,

interlinked network of a prepared healthcare team, making the case for collaboration not just persuasive, but essential for sustainable and high-quality care [20, 21, 22].

Deconstructing the Silo: Defining the Unique Role of Each Collaborator

The transition from a fragmented, specialist-centric model to an integrated, patient-centered system for thyroid care necessitates a fundamental deconstruction of professional silos. This process begins with a clear appreciation of the distinct, yet deeply complementary, expertise that each member of the interprofessional team contributes. Only by defining these unique roles can we orchestrate their synergies, creating a seamless continuum of care that addresses the multifaceted needs of the patient with a thyroid disorder. The core collaborative team comprises the family physician, the nurse, the pharmacist, and the laboratory staff, each acting as a vital node in a connected network rather than an isolated point of service.

The **surgery physician** serves as the strategic leader, diagnostic anchor, and longitudinal coordinator of care. As the first and most consistent point of contact, the family physician is uniquely positioned to recognize the subtle, nonspecific symptoms of thyroid dysfunction within the full context of the patient's medical, social, and family history. They synthesize information from the patient's narrative, physical examination findings (e.g., checking for goiter, delayed reflexes, or skin changes), and initial laboratory results to form a provisional diagnosis [23]. Their role extends far beyond this initial assessment; they are responsible for initiating treatment, interpreting ongoing laboratory monitoring in the context of the patient's overall clinical status, and managing comorbid conditions that interact with thyroid disease, such as cardiovascular risk factors or mood disorders. Crucially, the family physician acts as the "quarterback" of the team, making referrals to endocrinology when complexity demands it (e.g., suspected thyroid cancer, Graves' disease, pregnancy planning), while retaining primary oversight. They integrate the inputs from other team members a nurse's report of persistent fatigue, a pharmacist's note on adherence issues, a laboratory's flag about a confounding factor into a coherent, updated management plan [24].

The **nurse**, particularly in primary care or specialized chronic disease roles, is the linchpin of continuity, education, and holistic support. Nurses operationalize the management plan through structured, proactive follow-up. They conduct scheduled review appointments, often via telehealth or in-clinic visits, to assess symptom response, monitor for side effects, and check vital signs. A core nursing function is transformative patient education. They spend dedicated time explaining the chronic nature of thyroid disease, the importance of consistent medication timing, and the rationale behind lifelong monitoring, thereby demystifying the condition and empowering self-management [25]. Nurses provide empathetic counseling to address the anxiety and frustration often associated with the slow resolution of symptoms and dose adjustments. They also serve as a critical communication bridge, triaging patient concerns, relaying important clinical updates to the physician, and ensuring that no issue falls between the cracks. Their longitudinal relationship with the patient allows them to detect subtle deteriorations or adherence lapses that might not be apparent in a shorter physician consultation.

The **pharmacist** contributes a specialized layer of pharmaceutical expertise that directly safeguards therapeutic efficacy and prevents treatment failure. Their role transcends dispensing to active medication therapy management (MTM). Pharmacists perform crucial medication reconciliation to avoid interactions and ensure accuracy. They provide granular, practical counseling on levothyroxine administration: the imperative of taking it on an empty stomach with water only, waiting 30-60 minutes before eating or drinking anything else (especially coffee), and spacing it at least 4 hours apart from supplements containing calcium, iron, or multivitamins and drugs like proton pump inhibitors [26]. This counseling is not a one-time event but an ongoing reinforcement. Community pharmacists, who may see the patient monthly, are ideally placed to identify patterns of poor adherence through refill records and to gently re-educate. They can also advise on the appropriate use of over-the-counter products that may interfere with thyroid function or its testing, such as biotin supplements. By collaborating directly with the prescriber, the pharmacist can suggest dose adjustments based on their observations and recommend the most cost-effective, bioequivalent formulations, addressing both clinical and economic aspects of care.

The **laboratory staff and clinical biochemists** are the guardians of diagnostic integrity, providing the objective data upon which every clinical decision pivots. Their role is foundational and extends far beyond performing automated assays. They ensure the precision, accuracy, and reliability of thyroid function tests (TSH, Free T4, Free T3) through rigorous quality control [27]. A critical, often underappreciated, aspect of their work is identifying and investigating assay interferences. For example, they are trained to recognize patterns suggestive of heterophilic antibodies or the increasingly common problem of biotin interference from high-dose supplements, which can cause falsely low TSH or falsely high thyroid hormone levels [28]. When such interference is suspected, laboratory scientists communicate directly with the clinical team to recommend repeat testing with a different methodology or a biotin washout period. Furthermore, they can add immense value by formatting reports with clear reference ranges, flagging critically abnormal results for immediate attention, and providing interpretative comments. By acting as consultants on test selection and interpretation, they prevent diagnostic misadventures and ensure that the clinical team is working with trustworthy data.

The true power of this model lies not in the sum of these individual parts, but in their dynamic interaction. The process is cyclical and reinforcing: The physician diagnoses and prescribes based on laboratory data. The nurse educates the

patient using principles reinforced by the pharmacist. The pharmacist's counseling improves adherence, leading to more accurate laboratory results. The laboratory scientist alerts the team to a confounding factor, prompting the nurse to re-interview the patient about supplement use, and the pharmacist to provide specific advice, leading the physician to correctly interpret the results and avoid an unnecessary dose change. This is the antithesis of a silo. It is a continuous feedback loop of information, expertise, and action centered on the patient [29].

Deconstructing these silos requires intentional design. It involves creating shared care protocols that define communication pathways (e.g., when a pharmacist identifies non-adherence, they contact the nurse; when the lab detects interference, they alert the physician). It necessitates interprofessional education to foster mutual respect and understanding of each other's scopes of practice [30].

The Synergy in Action: Practical Models for Collaborative Thyroid Care

Translating the principles of interprofessional collaboration into tangible, daily practice requires the implementation of structured models that move beyond abstract ideals. For thyroid disorder management, practical collaborative frameworks are essential to orchestrate the distinct roles of family physicians, nurses, pharmacists, and laboratory staff into a synchronized, efficient, and patient-centered system. These models, grounded in chronic care and systems-thinking approaches, formalize communication, clarify accountability, and leverage each professional's expertise at the optimal point in the care continuum, thereby creating measurable synergy [31].

A cornerstone model is the development and implementation of **Standardized Clinical Pathways with Embedded Interprofessional Triggers**. These pathways are detailed, evidence-based algorithms that map the patient journey from initial suspicion of thyroid dysfunction through diagnosis, titration, and long-term maintenance. Crucially, they are not physician-centric workflows but are designed with explicit "hand-off" points and decision nodes that activate other team members. For example, a pathway for newly diagnosed hypothyroidism might automatically generate: 1) a referral to a nurse educator for a structured 45-minute session on disease understanding and medication administration, 2) a flag to the clinical pharmacist for a comprehensive medication review to address interactions and adherence barriers, and 3) a pre-scheduled laboratory follow-up order with clear instructions for the patient [32]. The pathway defines protocols for communication; for instance, if the pharmacist identifies a significant adherence issue, the pathway mandates an update to the nurse for reinforced counseling and an alert to the physician that the next TSH result may be unreliable for dose adjustment. This model reduces clinical variation, ensures no aspect of care is missed, and empowers non-physician providers to act within a secure, pre-authorized scope, thereby enhancing efficiency and safety.

The **Pharmacist-Led Chronic Disease Management Clinic**, specifically for thyroid disorders, is a powerful model that formally integrates pharmaceutical expertise into routine care. Patients with unstable labs, persistent symptoms, or complex medication regimens are scheduled for dedicated appointments with a clinical pharmacist operating under collaborative practice agreements. During these sessions, the pharmacist conducts in-depth medication therapy management (MTM), performing detailed adherence assessments, investigating the root cause of lab instability (e.g., pinpointing inconsistent timing or concurrent use of calcium supplements), and providing tailored education [33]. The pharmacist can then make formal, evidence-based recommendations to the physician for dose adjustments or order necessary lab tests as per protocol. Studies show such clinics significantly improve therapeutic TSH target attainment, reduce medication errors, and increase patient satisfaction by providing dedicated time to address pharmaceutical complexities that are often glossed over in busy physician appointments [34]. This model not only optimizes outcomes but also allows the family physician to focus on diagnostic evaluation and management of comorbidities.

To proactively address complex cases and foster a culture of collective problem-solving, the **Structured Interprofessional Team Huddle** is an invaluable model. These are brief, regular (e.g., weekly or bi-weekly), stand-up meetings focused on reviewing patients who are not meeting therapeutic goals. In a thyroid care context, the nurse might present a patient with ongoing fatigue despite normalized TSH. The laboratory professional can immediately verify the assay's validity and inquire about potential biotin interference. The pharmacist can review the medication list for interacting drugs. The family physician can contribute insights on potential alternative diagnoses like sleep apnea or depression. Within minutes, the team collectively devises a multifaceted action plan: holding biotin, checking a morning cortisol, screening for sleep apnea, and scheduling a follow-up MTM visit [35]. This model dismantles hierarchical barriers, facilitates real-time cross-consultation, and leverages the collective intelligence of the team to solve puzzles that would likely persist in a siloed setup.

Technology serves as the essential enabler of modern collaboration through the **Integrated Digital Health Platform with Collaborative Workflows**. An advanced Electronic Health Record (EHR) system, configured for teamwork, is the central nervous system of these models. Key functionalities include: 1) **Shared Care Plans** visible and editable by all team members, documenting patient-centered goals and assigned tasks. 2) **Automated Decision Support** that alerts the nurse when a TSH result returns outside the target range, prompting a standardized symptom assessment. 3) **Secure, Role-Based Messaging** that allows the pharmacist to directly message the physician with a dose change recommendation, complete with clinical rationale. 4) **Integrated Laboratory Dashboards** that allow clinicians to view trends and the lab to attach interpretive comments directly to anomalous results [36]. Furthermore, patient portals can extend this synergy to include the patient, allowing them to report symptoms, view lab results, and receive

automated educational materials tailored to their condition. This digital infrastructure ensures that information flows securely and efficiently, preventing the communication breakdowns that plague fragmented systems.

Finally, redefining the relationship with diagnostic services through the **Laboratory as an Active Clinical Consultant** model closes the quality loop. This involves moving from a transactional "order-result" relationship to a partnership. Laboratories can implement proactive procedures such as calling critical or dramatically discrepant results directly to the ordering clinician *and* the assigned care coordinator. Clinical biochemists can offer interpretive services for complex thyroid function panels, helping to distinguish between true disease and assay artifact [37].

Measuring Success: Impact of Collaboration on Key Patient Outcomes in Thyroid Disorders

The ultimate validation of any healthcare intervention lies in its measurable impact on patient outcomes. For the collaborative management of thyroid disorders, moving from theoretical benefits to demonstrable improvements is crucial for justifying systemic change and securing ongoing investment. The shift from a fragmented to an integrated, team-based approach positively influences a spectrum of outcomes, spanning clinical, humanistic, and economic domains. By defining and tracking these metrics, healthcare systems can concretely evidence the value of breaking down professional silos in thyroid care [38].

The most direct clinical outcome influenced by collaboration is the **rate of achieving and maintaining biochemical euthyroidism**. Optimal thyroid-stimulating hormone (TSH) levels are the cornerstone of effective management for conditions like hypothyroidism. In siloed care, inconsistent messaging about medication timing, poor adherence due to a lack of understanding, and delayed dose adjustments can lead to prolonged periods of suboptimal control. Collaborative models directly address these gaps. Pharmacist-led medication therapy management (MTM) and nurse-led reinforcement of administration protocols significantly improve adherence—a primary driver of stable TSH levels [39]. Furthermore, structured pathways with pre-defined monitoring schedules and clear titration protocols, often managed by nurses under standing orders, ensure that lab abnormalities are acted upon promptly. Studies of pharmacist-managed thyroid clinics have shown statistically significant improvements in the percentage of patients within the therapeutic TSH range compared to usual care, with one study demonstrating an increase from 47% to 78% of patients achieving target levels [40]. This biochemical optimization is the fundamental prerequisite for alleviating symptoms and preventing long-term complications.

Beyond laboratory numbers, collaboration profoundly enhances **patient-reported outcomes (PROs) and quality of life (QoL)**. The nonspecific but debilitating symptoms of thyroid dysfunction—fatigue, cognitive complaints, mood disturbances—are the primary concern for patients. A team-based model improves QoL through several mechanisms. First, the consistent education and empathetic support provided by nurses and pharmacists reduce the anxiety and frustration associated with a chronic condition, fostering a sense of empowerment and self-efficacy [41]. Second, by achieving biochemical control more reliably and swiftly, physical and mental symptoms abate faster. Third, the holistic perspective of the team allows for better identification and management of overlapping conditions (e.g., depression, fibromyalgia) that may contribute to symptom burden. Research indicates that patients receiving care from coordinated teams report significantly better scores on thyroid-specific QoL questionnaires, noting improvements in energy levels, emotional well-being, and overall daily functioning compared to those in traditional care models [42]. This humanistic impact is arguably the most meaningful measure of success from the patient's perspective.

Collaboration also yields significant improvements in **safety outcomes and the reduction of preventable harm**. Thyroid medication errors and adverse drug events (ADEs) are common in fragmented systems. These can include incorrect dosing, dangerous interactions (e.g., levothyroxine and anticoagulants), and the consequences of untreated drug-induced hypothyroidism from amiodarone or lithium. The pharmacist's integrated role as a medication expert acts as a powerful safeguard. Through systematic reconciliation and review, pharmacists intercept prescribing errors, identify high-risk interactions, and counsel to prevent administration errors [33]. The laboratory's proactive role in identifying and communicating assay interferences (e.g., from biotin or heterophilic antibodies) prevents misdiagnosis and inappropriate, potentially harmful, dose changes [37]. Furthermore, structured communication channels, such as team huddles, create a culture of collective vigilance where potential safety issues can be flagged by any team member before they reach the patient. This multi-layered safety net directly reduces iatrogenic harm.

From a system efficiency standpoint, collaborative care positively impacts **healthcare utilization metrics**. By empowering nurses and pharmacists to manage stable follow-up, dose titrations, and patient education, family physicians can focus their time on complex diagnostic and management issues, potentially improving access for all patients. Effective collaboration reduces the need for unnecessary specialist endocrinology referrals for routine management, reserving specialist expertise for truly complex cases like thyroid cancer or resistant Graves' disease [43]. Moreover, by preventing complications of uncontrolled disease (e.g., cardiovascular events, severe osteoporosis) through better overall management, collaborative models can reduce rates of emergency department visits and hospital admissions related to thyroid disorders. While longitudinal data is still emerging, early economic analyses suggest that the upfront investment in team-based structures is offset by reductions in downstream costs associated with poor disease control and avoidable utilization [44].

Finally, a critical and often overlooked outcome is **professional satisfaction and team efficacy**. Burnout among healthcare professionals is frequently fueled by systemic inefficiency, chaotic workflows, and a sense of working in

isolation against complex problems. Implementing collaborative models with clear roles, shared responsibility, and efficient communication can mitigate these factors. When professionals feel their unique expertise is utilized effectively within a supportive team, job satisfaction and morale improve [45]. This, in turn, reduces staff turnover and fosters a positive practice environment, which indirectly but powerfully benefits patient care through continuity and engaged providers. Measuring this can involve staff surveys assessing autonomy, clarity of roles, and perceived effectiveness of teamwork [45].

Navigating the Challenges: Barriers to Effective Interprofessional Practice in Thyroid Disorders

Despite the compelling evidence supporting interprofessional collaboration (IPC) for improving thyroid care, its widespread and effective implementation faces substantial, deeply rooted barriers. Translating the theoretical model into daily practice requires navigating a complex landscape of systemic, professional, cultural, and logistical obstacles. Acknowledging and understanding these challenges is a critical first step toward developing targeted strategies to overcome them, ensuring that the synergistic potential of team-based care is fully realized rather than remaining an unfulfilled aspiration [46].

One of the most persistent and formidable barriers is the **entrenched culture of professional hierarchies and territoriality**. Healthcare has historically been structured around a physician-centric model, where the doctor is viewed as the sole captain of the ship. This deeply ingrained hierarchy can stifle the open communication and shared decision-making essential for collaboration. Nurses, pharmacists, and laboratory scientists may hesitate to voice concerns or suggestions due to perceived power imbalances, fear of overstepping boundaries, or previous experiences where their input was dismissed [47]. Conversely, some physicians may feel that collaborative models diminish their autonomy or authority, leading to resistance. In thyroid care, this might manifest as a physician dismissing a pharmacist's detailed report on a patient's adherence patterns or a laboratory scientist feeling unable to call a clinician directly about a critically anomalous result. This "silo mentality" protects professional domains but at the direct expense of integrated patient care. Overcoming this requires a fundamental cultural shift towards valuing each profession's unique expertise as equally vital to the patient's outcome.

Closely related are **ambiguities in scope of practice and role confusion**. Even when collaboration is encouraged, the specific responsibilities of each team member in thyroid management can be poorly defined. Can a nurse adjust a levothyroxine dose based on a protocol, or must every change go through the physician? Is the pharmacist authorized to order a follow-up TSH test? Without clear, legally supported, and mutually agreed-upon parameters, team members may either hold back from acting to their full capability (leading to delays) or step into areas where they lack formal training or authorization, creating liability concerns [48]. This ambiguity breeds inefficiency and frustration. For example, a nurse aware of a patient's ongoing symptoms may spend time tracking down a physician for a simple dose adjustment that a protocol could empower them to make, while the physician's time is consumed by tasks that other team members are better positioned to handle. Establishing collaborative practice agreements (CPAs) and detailed clinical protocols is essential to delineate roles clearly, but their creation and adoption themselves face bureaucratic and regulatory hurdles.

Inefficient or incompatible information systems pose a massive technological barrier to seamless collaboration. Many Electronic Health Record (EHR) systems are designed for billing and single-provider documentation, not for team-based care. Critical information may be siloed within different modules or inaccessible to certain professional groups due to restrictive access controls. A pharmacist in a community setting may have no view of the primary care EHR, relying on fragmented paper prescriptions. Laboratory results might populate the physician's inbox but not generate an automated alert for the assigned care coordinator nurse [49]. Communication often defaults to inefficient methods like phone tag or unsecure messaging. This lack of a shared, real-time information platform forces professionals to work with incomplete data, duplicates efforts, and makes coordinated care planning exceedingly difficult. For thyroid management, where medication timing, lab trends, and symptom reports are interconnected, this technological fragmentation directly undermines the goal of integrated care.

Significant **resource constraints and misaligned financial incentives** create a stark economic disincentive for collaboration. Current reimbursement models in many healthcare systems predominantly reward volume-based, physician-delivered services. There is often little to no payment for the time a pharmacist spends conducting an MTM session, a nurse spends on extended patient education, or a team spends in a care coordination huddle [50]. These activities, though proven to improve outcomes, are viewed as non-reimbursable overhead. Practices operating under tight financial margins cannot easily justify dedicating staff time to collaborative activities that are not directly billable. Furthermore, physical space, dedicated administrative support, and time for team meetings are often scarce resources. The economic structure of healthcare, therefore, actively penalizes the very collaborative processes it purports to desire, creating a major practical impediment to sustainable implementation.

Finally, a **deficit in interprofessional education (IPE) and training** means that many healthcare professionals enter practice unprepared for collaborative work. Traditional education trains professions in isolation—nurses with nurses, pharmacists with pharmacists—fostering the very silos that later need to be broken down. Graduates may lack the skills necessary for effective teamwork, such as conflict resolution, understanding other professions' lexicons and values, and practicing shared leadership [51]. In the context of thyroid care, a physician may not fully understand the

depth of a clinical pharmacist's therapeutic knowledge, while a pharmacist may not appreciate the complexity of a family physician's diagnostic reasoning across multiple comorbidities. Without foundational IPE that includes joint case studies on conditions like thyroid disorders, professionals lack the mutual respect and common language required for high-functioning teams. This educational gap must be addressed at both the pre-licensure and continuing professional development levels [52].

A Roadmap for Integration: Recommendations for Implementation and Future Directions

The journey toward fully integrated, interprofessional thyroid care requires a deliberate and strategic roadmap. Moving beyond identifying barriers, healthcare systems, policymakers, educational institutions, and professional bodies must collaborate to enact concrete solutions. This final section proposes a multi-tiered set of recommendations for implementation and outlines critical future directions for research and policy, aiming to transform the collaborative model from a promising concept into a standard of care for thyroid disorders [53].

1. Policy and Payment Reform: Aligning Incentives with Integration

The most powerful lever for change is the restructuring of financial incentives. Sustainable collaboration cannot rely on altruism alone; it must be economically viable. Recommendations include:

- **Developing and Funding Collaborative Care Codes:** Payers (government and private insurers) must create and adequately reimburse billing codes for team-based activities. This includes codes for pharmacist-led Medication Therapy Management (MTM) visits, nurse-led chronic disease management visits, and interprofessional care coordination time, specifically for conditions like thyroid disorders [54].

- **Implementing Value-Based Payment Models:** Shifting from fee-for-service to value-based or capitated payment models incentivizes population health outcomes. In such models, preventing complications and optimizing control in chronic thyroid disease becomes a financial priority, naturally encouraging investment in collaborative, preventive team structures [55].

- **Providing Start-up and Infrastructure Grants:** Governments and healthcare organizations should offer targeted funding to support the initial development of collaborative thyroid clinics, including costs for workflow redesign, interprofessional training, and technology integration.

2. Operational and Structural Recommendations: Building the Framework

At the organizational level, clinical leaders must architect the systems that enable daily collaboration.

- **Co-Create Formalized Protocols and Agreements:** Each practice or health network should establish thyroid-specific, interprofessional clinical pathways. These must be developed *with* input from all professions (physicians, nurses, pharmacists, lab staff) to ensure buy-in and practicality. These pathways should be accompanied by signed Collaborative Practice Agreements (CPAs) that legally define and authorize role expansions, such as nurse-initiated dose titration or pharmacist-ordered monitoring labs under specific protocols [56].

- **Invest in Interoperable Health Technology:** EHR systems must be configured or chosen to facilitate teamwork. This requires functionalities like: a shared care plan visible to all, secure team messaging, automated task assignment based on results (e.g., a high TSH triggers a task for the nurse), and integrated dashboards for population management of all thyroid patients. Interoperability between primary care EHRs, pharmacy systems, and laboratory information systems is non-negotiable for seamless information flow [57].

- **Dedicate Time and Space for Team Functioning:** Administration must formally schedule and protect time for regular interprofessional huddles and case conferences. This includes providing physical or virtual meeting spaces and considering this time a core clinical activity, not an administrative add-on.

3. Educational and Cultural Transformation: Preparing the Workforce

A collaborative system requires a workforce trained and socialized to work within it.

- **Integrate IPE into Curricula and Continuing Education:** Interprofessional Education (IPE) must be embedded in undergraduate and postgraduate training for all health professions. Joint learning modules using thyroid disorder case studies can teach students about each other's roles, communication strategies, and shared problem-solving before they enter practice [58]. Mandatory continuing education on teamwork and IPC should be promoted by professional colleges.

- **Foster Leadership and "Champions":** Identify and empower clinical champions from each profession—a physician advocate, a nurse lead, a clinical pharmacist—to drive the change locally, mentor colleagues, and model collaborative behavior. Leadership training should focus on facilitative and shared leadership models rather than traditional top-down authority [59].

- **Implement Team Performance Metrics and Feedback:** Develop and track metrics not just for patient outcomes, but for team performance. This could include measures of referral patterns, closed-loop communication completion rates, and staff satisfaction surveys on psychological safety and teamwork. Regularly reviewing this data as a team fosters a culture of continuous quality improvement in the collaborative process itself.

4. Future Research Directions

While the foundational evidence is strong, targeted research is needed to refine and advance the model.

- **Economic Evaluations:** Rigorous cost-effectiveness and return-on-investment studies are needed to quantify the long-term economic value of collaborative thyroid care, capturing savings from reduced complications, hospitalizations, and specialist referrals to offset upfront costs [60].
- **Technology and Implementation Science:** Research should focus on designing, testing, and optimizing digital tools specifically for interprofessional thyroid management (e.g., shared decision-support apps, patient-reported outcome integrators). Implementation science studies are crucial to identify the most effective strategies for adopting collaborative models across diverse healthcare settings (rural vs. urban, different countries) [61].
- **Patient as Partner:** Future models should research deeper integration of the patient as a formal member of the care team. This involves studying tools and methods for shared goal-setting, self-management support, and how patient-generated health data can be optimally incorporated into team-based decision-making [62].
- **Expanding the Scope:** Research should explore the extension of this collaborative model to more complex thyroid conditions, such as the post-surgical management of thyroid cancer (integrating surgeons, endocrinologists, and nuclear medicine) or the management of thyroid eye disease in Graves' disease (integrating ophthalmology) [63].

CONCLUSION

In conclusion, the management of thyroid disorders presents a compelling and urgent case for a paradigm shift from fragmented, specialist-centric care to a coordinated, interprofessional model. The multifaceted burden of these conditions encompassing diagnostic complexity, lifelong treatment, and substantial personal and economic costs cannot be optimally addressed within the constraints of traditional professional silos. As demonstrated, a collaborative framework that strategically leverages the distinct competencies of the family physician (diagnosis and coordination), the nurse (education and continuity), the pharmacist (medication safety and adherence), and the laboratory professional (diagnostic accuracy) creates a synergistic system greater than the sum of its parts.

This integration leads to tangible improvements across the spectrum of care: achieving biochemical euthyroidism more reliably, enhancing patients' quality of life, preventing adverse drug events, and using healthcare resources more efficiently. While the path forward is challenged by entrenched hierarchies, technological gaps, and financial disincentives, these barriers are not insurmountable. They demand a concerted, systemic effort focused on value-based payment reform, the co-creation of clear clinical protocols, investment in interoperable health technology, and foundational interprofessional education.

The future of high-quality thyroid care lies in formalized teamwork. By committing to the implementation roadmap—which aligns policy, practice, and education—healthcare systems can ensure that every patient with a thyroid disorder receives comprehensive, coherent, and compassionate care. This evolution is not merely an administrative change but a fundamental recommitment to patient-centered principles, promising a future where improved outcomes are consistently realized through the power of collective expertise and shared purpose.

REFERENCES:

1. Graneheim UH, Lundman B. Qualitative content analysis in nursing research: Concepts, procedures and measures to achieve trustworthiness. *Nurse Educ Today*. 2004;24:105–12. doi: 10.1016/j.nedt.2003.10.001. [DOI] [PubMed] [Google Scholar]
2. World Health Organization. Framework for Action on Interprofessional Education and Collaborative Practice. Geneva, Switzerland: World Health Organization; 2010. [[Last accessed on 2023 May 20]]. Available from: <https://www.who.int/publications/i/item/framework-for-action-on-interprofessional-education-collaborative-practice>. [Google Scholar]
3. D'amour D, Oandasan I. Interprofessionality as the field of interprofessional practice and interprofessional education: An emerging concept. *J Interprof Care*. 2005;19:8–20. doi: 10.1080/13561820500081604. [DOI] [PubMed] [Google Scholar]
4. De Baetselier E, Dilles T, Batalha LM, Dijkstra NE, Fernandes MI, Filov I, et al. Perspectives of nurses'role in interprofessional pharmaceutical care across 14 European countries: A qualitative study in pharmacists, physicians and nurses. *PLoS One*. 2021;16:e0251982. doi: 10.1371/journal.pone.0251982. [DOI] [PMC free article] [PubMed] [Google Scholar]
5. Makowsky MJ, Schindel TJ, Rosenthal M, Campbell K, Tsuyuki RT, Madill HM. Collaboration between pharmacists, physicians and nurse practitioners: A qualitative investigation of working relationships in the inpatient medical setting. *J Interprof Care*. 2009;23:169–84. doi: 10.1080/13561820802602552. [DOI] [PubMed] [Google Scholar]
6. Eikey EV, Reddy MC, Kuziemy CE. Examining the role of collaboration in studies of health information technologies in biomedical informatics: A systematic review of 25 years of research. *J Biomed Inform*. 2015;57:263–77. doi: 10.1016/j.jbi.2015.08.006. [DOI] [PubMed] [Google Scholar]

7. Alsuhbany N, Alfehaid L, Almodaimegh H, Albekairy A, Alharbi S. Attitude and perception of physicians and nurses toward the role of clinical pharmacists in Riyadh, Saudi Arabia: A qualitative study. *SAGE Open Nurs.* 2019;5:2377960819889769. doi: 10.1177/2377960819889769. [DOI] [PMC free article] [PubMed] [Google Scholar]
8. World Health Organization. Framework for Action on Interprofessional Education and Collaborative Practice. Geneva, Switzerland: World Health Organization; 2010. [[Last accessed on 2023 May 20]]. Available from: <https://www.who.int/publications/i/item/framework-for-action-on-interprofessional-education-collaborative-practice>. [Google Scholar]
9. Håkansson Lindqvist M, Gustafsson M, Gallego G. Exploring physicians, nurses and ward-based pharmacists working relationships in a Swedish inpatient setting: A mixed methods study. *Int J Clin Pharm.* 2019;41:728–33. doi: 10.1007/s11096-019-00812-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
10. Jasemi M, Valizadeh L, Zamanzadeh V, Keogh B. A concept analysis of holistic care by hybrid model. *Indian J Palliat Care.* 2017;23:71–80. doi: 10.4103/0973-1075.197960. [DOI] [PMC free article] [PubMed] [Google Scholar]
11. Saint-Pierre C, Herskovic V, Sepúlveda M. Multidisciplinary collaboration in primary care: A systematic review. *Fam Pract.* 2018;35:132–41. doi: 10.1093/fampra/cmz085. [DOI] [PubMed] [Google Scholar]
12. Ndibu Muntu Keba Kebe N, Chiocchio F, Bamvita J-M, Fleury M-J. Variables associated with interprofessional collaboration: A comparison between primary healthcare and specialized mental health team. *BMC Fam Pract.* 2020;21:4. doi: 10.1186/s12875-019-1076-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
13. Waszyk-Nowaczyk M, Guzenda W, Dragun P, Olsztyńska L, Liwarska J, Michalak M, et al. Interdisciplinary cooperation between pharmacists and nurses-experiences and expectations. *Int J Environ Res Public Health.* 2022;19:11713. doi: 10.3390/ijerph191811713. [DOI] [PMC free article] [PubMed] [Google Scholar]
14. Liu W, Gerdzt M, Manias E. Creating opportunities for interdisciplinary collaboration and patient-centred care: How nurses, doctors, pharmacists and patients use communication strategies when managing medications in an acute hospital setting. *J Clin Nurs.* 2016;25:2943–57. doi: 10.1111/jocn.13360. [DOI] [PubMed] [Google Scholar]
15. Makowsky MJ, Schindel TJ, Rosenthal M, Campbell K, Tsuyuki RT, Madill HM. Collaboration between pharmacists, physicians and nurse practitioners: A qualitative investigation of working relationships in the inpatient medical setting. *J Interprof Care.* 2009;23:169–84. doi: 10.1080/13561820802602552. [DOI] [PubMed] [Google Scholar]
16. Merriam-Webster Collaborate: In Merriam-Webster.com dictionary; Retrieved 11 February. 2022 [Google Scholar]
17. Wehmeier S, McIntosh C, Turnbull J, Ashby M, Hornby AS. Oxford University Press; UK: Oxford: 2005. Oxford Advanced Learner's Dictionary: Of Current English. [Google Scholar]
18. White-Williams C, Shirey MR. Taking an interprofessional collaborative practice to the next level: Strategies to promote high performing teams. *J Interprof Educ Pract.* 2022;26:100485. [Google Scholar]
19. Mulvale G, Embrett M, Razavi SD. 'Gearing Up' to improve interprofessional collaboration in primary care: A systematic review and conceptual framework. *BMC Fam Pract.* 2016;17:83. doi: 10.1186/s12875-016-0492-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
20. World Health Organization. Framework for Action on Interprofessional Education and Collaborative Practice. Geneva, Switzerland: World Health Organization; 2010. [[Last accessed on 2023 May 20]]. Available from: <https://www.who.int/publications/i/item/framework-for-action-on-interprofessional-education-collaborative-practice>. [Google Scholar]
21. Armin A, Akib H, Limpo HY, Thamrin A, Mustari M. Collaborative Partnership in Management of Community Health Centers (PUSKESMAS) in Wajo Regency, Indonesia. In International Conference on Public Organization ('ICONPO) 2019. [[Last accessed on 2020 Dec 18]]. Available from: <https://ssrn.com/abstract=3497244>.
22. Wang J, Guo J, Wang Y, Yan D, Liu J, Zhang Y, et al. Use of profession-role exchange in an interprofessional student team-based community health service-learning experience. *BMC Med Edu.* 2020;20:212. doi: 10.1186/s12909-020-02127-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
23. World Health Organization. Framework for Action on Interprofessional Education and Collaborative Practice. Geneva, Switzerland: World Health Organization; 2010. [[Last accessed on 2023 May 20]]. Available from: <https://www.who.int/publications/i/item/framework-for-action-on-interprofessional-education-collaborative-practice>. [Google Scholar]
24. Geese F, Schmitt KU. Interprofessional collaboration in complex patient care transition: A qualitative multi-perspective analysis. *Healthcare (Basel, Switzerland)* 2023;11:359. doi: 10.3390/healthcare11030359. [DOI] [PMC free article] [PubMed] [Google Scholar]
25. House S, Wilmoth M, Kitzmiller R. Relational coordination and staff outcomes among healthcare professionals: A scoping review. *J Interprof Care.* 2022;36:891–9. doi: 10.1080/13561820.2021.1965101. [DOI] [PubMed] [Google Scholar]
26. van Welie S, Wijma L, Beerden T, Van Doormaal J, Taxis K. Effect of warning symbols in combination with education on the frequency of erroneously crushing medication in nursing homes: an uncontrolled before and after study. *BMJ Open.* 2016;e012286. doi: 10.1136/BMJOPEN-2016-012286.

27. Zamfirescu I, Carlson HE. Absorption of Levothyroxine when coadministered with various calcium formulations. *Thyroid: Official J Am Thyroid Association*. 2011;21:483–6.
28. Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, et al. Guidelines for the treatment of hypothyroidism: prepared by the American thyroid association task force on thyroid hormone replacement. *Thyroid*. 2014;24:1670.
29. Joon-Kalarickal J, Pearlman G, Carlson HE. New medications which decrease Levothyroxine absorption. *Thyroid: Official J Am Thyroid Association*. 2007;17:763–5.
30. Yavuz DG, Yazici D, Keskin L, Atmaca A, Sancak S, Saraç F, et al. Out-of-Reference range Thyroid-Stimulating hormone levels in Levothyroxine-Treated primary hypothyroid patients: A multicenter observational study. *Front Endocrinol*. 2017;8:215.
31. Chaker L, Bianco AC, Jonklaas J, Peeters RP, Hypothyroidism. *Lancet*. 2017;390(17):1550–62.
32. Santini F, Pinchera A, Marsili A, Ceccarini G, Castagna MG, Valeriano R, et al. Lean body mass is a major determinant of Levothyroxine dosage in the treatment of thyroid diseases. *J Clin Endocrinol Metab*. 2005;90:124–7.
33. Guaman-Prado Y, Vita R, Samson O. Concomitant use of Levothyroxine and proton pump inhibitors in patients with primary hypothyroidism: a systematic review. *J Gen Intern Med*. 2021;36:1726–33.
34. Iyer K, Dilipkumar N, Vasaya S, Pawar S, Diwan A. Comparison of drug related problems associated with use of narrow therapeutic index drugs and other drugs in hospitalized patients. *J Young Pharmacists*. 2018;10:318–21.
35. Irving SA, Vadiveloo T, Leese GP. Drugs that interact with levothyroxine: an observational study from TEARS. *Clin Endocrinol*. 2015;82:136–41.
36. Singh N, Singh PN, Hershman JM. Effect of calcium carbonate on the absorption of Levothyroxine. *JAMA*. 2000;283:2822–5.
37. Rdzak GM, Whitman LM, Inzucchi SE. Levothyroxine pseudo-malabsorption: testing and treatment in the outpatient setting. *Therapeutic Adv Endocrinol Metabolism*. 2018;9:217–22.
38. Guzman-Prado Y, Vita R, Samson O. Concomitant use of Levothyroxine and proton pump inhibitors in patients with primary hypothyroidism: a systematic review. *J Gen Intern Med*. 2021;36:1726–33.
39. Langebrake C, Ihbe-Heffinger A, Leichenberg K, Kaden S, Kunkel M, Lueb M, et al. Nationwide evaluation of day-to-day clinical pharmacists' interventions in German hospitals. *Pharmacotherapy*. 2015;35(4):370–9.
40. Schorr SG, Eickhoff C, Feldt S, Hohmann C, Schulz M, Schulz M. Exploring the potential impact of hospital ward-based pharmacy interns on drug safety. *Pharmazie*. 2014;69:316–20.
41. Irving SA, Vadiveloo T, Leese GP. Drugs that interact with levothyroxine: an observational study from TEARS. *Clin Endocrinol*. 2015;82:136–41.
42. Wiersinga WM. Paradigm shifts in thyroid hormone replacement therapies for hypothyroidism. *Nat Rev Endocrinol*. 2014;10:164–74.
43. Santini F, Pinchera A, Marsili A, Ceccarini G, Castagna MG, Valeriano R, et al. Lean body mass is a major determinant of Levothyroxine dosage in the treatment of thyroid diseases. *J Clin Endocrinol Metab*. 2005;90:124–7.
44. Zamfirescu I, Carlson HE. Absorption of Levothyroxine when coadministered with various calcium formulations. *Thyroid: Official J Am Thyroid Association*. 2011;21:483–6.
45. Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, et al. Guidelines for the treatment of hypothyroidism: prepared by the American thyroid association task force on thyroid hormone replacement. *Thyroid*. 2014;24:1670.
46. Saboula N. E., Ahmed N. A., Rashad R. H. Effect of nursing intervention on knowledge, attitude and self-care activities among gestational diabetic women. *International Journal of Novel Research in Healthcare and Nursing*. 2018;5(2):135–146.
47. Desmawati D., Kongsuwan W., Chatchawet W. The effects of childbirth preparation nursing intervention integrating Islamic praying program on duration of labor and neonatal outcomes in primiparous Muslim women. *Walailak Journal of Science and Technology (WJST)*. 2020;17(10):1048–1059. doi: 10.48048/wjst.2020.5456.
48. Shao J., Xiao T., Shi M., et al. Effect of multimedia-based nursing visit on perioperative anxiety in esophageal squamous cell carcinoma patients undergoing video-assisted thoracoscopic surgery. *Psychology, Health & Medicine*. 2019;24(10):1198–1206. doi: 10.1080/13548506.2019.1595687.
49. Wang J., Han F. Influence of psychological nursing intervention on the scores of parturient in the process of delivery and their depression before and after delivery. *Investigación Clínica*. 2020;61(1):261–268.
50. Qian C., Xu X., Zhang J., Zhong W., Yang X., Wang L. Nursing intervention of traditional Chinese medicine on constipation of senile rats with rheumatoid arthritis. *Revista Científica de la Facultad de Ciencias Veterinarias*. 2020;30(4):2144–2153.
51. Hao Hefnawy K. A., Zaghla H. M. Effect of nursing intervention program on interferone side effects among hepatitis C patients. *International journal of Nursing Didactics*. 2017;7(2):9–17.
52. Liu Y., Shan Z., Endocrine Metabolic Diseases Group of the Chinese Geriatrics Society, et al. Expert consensus on diagnosis and treatment for elderly with thyroid diseases in China (2021). *Aging Medicine*. 2021;4(2):70–92.

53. Cao S., Wu X., Zhao J., Jia X. Clinical study of the treatment of *Klebsiella pneumoniae* with comprehensive nursing intervention combined with new nano silver. *Journal of Nanoscience and Nanotechnology*. 2020;20(10):6063–6069.
54. Olga Q. Z. M., ClaudiaFI M. T. G. R. Effect of nursing interventions for stress management. *Hospice & Palliative Medicine International Journal*. 2018;2(2):100–106.
55. Xue G., Yi H., Xue P., Sun W. The effects of humanized psychological nursing model in general surgery nursing. *Proceedings of Anticancer Research*. 2021;5(4):98–102. DOI: 10.26689/par.v5i4.2356.
56. Miyakis S, Karamanof G, Lontos M, Mountokalakis TD. Factors contributing to inappropriate ordering of tests in an academic medical department and the effect of an educational feedback strategy. *Postgrad Med J*. 2006;82:823–829.
57. Zhelev Z, Abbott R, Rogers M, et al. Effectiveness of interventions to reduce ordering of thyroid function tests: a systematic review. *BMJ Open*. 2016;6:e010065.
58. Vidyarthi A, Hamill T, Green A, Rosenbluth G, Baron RB. Changing resident test ordering behavior: a multilevel intervention to decrease laboratory utilization at an academic medical center. *Am J Med Qual*. 2015;30(1):81–87.
59. Van Walraven C, Naylor CD. Do we know what inappropriate laboratory utilization is? a systematic review of laboratory clinical audits. *JAMA*. 1998;280(6):550–558.
60. Meidani Z, Farzandipour M, Farrokhian A, Haghighat M. A review on laboratory tests' utilization: a trigger for cutting costs and quality improvement in health care settings. *Med J Islam Rep Iran*. 2016;30:365.
61. Dey R., de Vries M., Bosnic-Anticevich S. Collaboration in chronic care: unpacking the relationship of pharmacists and general medical practitioners in primary care. *Int. J. Pharm. Pract*. 2011;19:21–29.
62. Drinka T. J. K., Clark P. G. Ch 5 The Science and Art of Interdisciplinary Practice, in *Health Care Teamwork: Interdisciplinary Practice and Teaching*. Westport, CT: Auburn House, 2000.
63. Card S. E., Ward H. A., Chipperfield D., Sheppard S. Postgraduate internal medicine residents roles at patient discharge—do the perceived roles and perceptions by other healthcare providers correlate? *J. Interprof Care*. 2013. 1–3.